{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:16:08Z","timestamp":1790972168666,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This research was funded by Gilead Sciences and Phenex Pharmaceuticals","award":["GS9674"],"award-info":[{"award-number":["GS9674"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NASH. Methods: NASH was induced in Wistar rats using a choline-deficient high-fat diet plus intraperitoneal sodium nitrite injections. First, a dose-finding study was performed with 10 mg\/kg and 30 mg\/kg of cilofexor, focusing on histological readouts. Liver fibrosis was assessed by Picro-Sirius-Red, desmin staining and hepatic hydroxyproline content. Gene expression was determined by RT-PCR. In a subsequent hemodynamic study, rats received 30 mg\/kg cilofexor with or without propranolol (25 mg\/kg). Portal pressure, systemic hemodynamics and splanchnic blood flow were measured. Results: Cilofexor dose-dependently induced FXR target genes shp, cyp7a1 and fgf15 in hepatic and ileal tissues, paralleled by a dose-dependent reduction in liver fibrosis area (Picro-Sirius-Red) of \u221241% (10 mg\/kg) and \u221269% (30 mg\/kg), respectively. The 30 mg\/kg cilofexor dose significantly reduced hepatic hydroxyproline content (\u221241%), expression of col1a1 (\u221237%) and pdgfr-\u03b2 (\u221236%), as well as desmin area (\u221242%) in NASH rats. Importantly, cilofexor decreased portal pressure (11.9 \u00b1 2.1 vs. 8.9 \u00b1 2.2 mmHg; p = 0.020) without affecting splanchnic blood-flow or systemic hemodynamics. The addition of propranolol to cilofexor additionally reduced splanchnic inflow (\u221228%) but also mean arterial pressure (\u221225%) and heart rate (\u221237%). Conclusion: The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats. While cilofexor seems to primarily decrease sinusoidal resistance in cirrhotic portal hypertension, the combination with propranolol additionally reduced mesenteric hyperperfusion.<\/jats:p>","DOI":"10.3390\/biomedicines9010060","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:55:56Z","timestamp":1610308556000},"page":"60","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-8076","authenticated-orcid":false,"given":"Philipp","family":"Schwabl","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hambruch","sequence":"additional","affiliation":[{"name":"Phenex Pharmaceuticals AG, 69123 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant R.","family":"Budas","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9998-262X","authenticated-orcid":false,"given":"Paul","family":"Supper","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-5441","authenticated-orcid":false,"given":"Michael","family":"Burnet","sequence":"additional","affiliation":[{"name":"Synovo GmbH, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Liles","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Birkel","sequence":"additional","affiliation":[{"name":"Phenex Pharmaceuticals AG, 69123 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia","family":"Brusilovskaya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"K\u00f6nigshofer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-2728","authenticated-orcid":false,"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Internal Medicine and Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology, and Nephrology with Centralized Emergency Service (ZAE), Klinikum Klagenfurt am W\u00f6rthersee, 9020 Klagenfurt, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Breckenridge","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc., Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Kremoser","sequence":"additional","affiliation":[{"name":"Phenex Pharmaceuticals AG, 69123 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), 1090 Vienna, Austria"},{"name":"CeMM Research Center for Molecular Medicine, The Austrian Academy of Sciences, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"ref_1","first-page":"81","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1159\/000375353","article-title":"Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH","volume":"33","author":"Traussnigg","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"Baveno","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mandorfer, M., Kozbial, K., Schwabl, P., Chromy, D., Semmler, G., Stattermayer, A.F., Pinter, M., Hernandez-Gea, V., Fritzer-Szekeres, M., and Steindl-Munda, P. (2019). Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology.","DOI":"10.1002\/hep.30885"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.28836","article-title":"Liver Capsule: FXR agonists against liver disease","volume":"64","author":"Fuchs","year":"2016","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Patel, K., Harrison, S.A., Elkashab, M., Trotter, J.F., Herring, R., Rojter, S., Kayali, Z., Wong, V.W., Greenbloom, S., and Jayakumar, S. (2020). Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology.","DOI":"10.1002\/hep.31205"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60017-9","article-title":"Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: A proof of concept phase 2a study","volume":"60","author":"Mookerjee","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3164\/jcbn.09-29","article-title":"A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH","volume":"45","author":"Takayama","year":"2009","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_15","first-page":"574A","article-title":"Evaluation of the Safety and Pharmacokinetic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers","volume":"64","author":"Kirby","year":"2016","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/S0168-8278(16)01682-2","article-title":"FXR agonism by GS-9674 decreases steatosis and fibrosis in a murine model of NASH","volume":"64","author":"Liles","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_17","first-page":"1009A","article-title":"FXR Agonist GS-9674 Decreases Hepatic Fibrosis in a Mouse Model of Advanced Fibrosis Due to Nash","volume":"68","author":"Liu","year":"2018","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cyto.2005.06.005","article-title":"Expression patterns of PDGF-A, -B, -C and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells (HSC)","volume":"31","author":"Breitkopf","year":"2005","journal-title":"Cytokine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/S0618-8278(19)31568-3","article-title":"Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD","volume":"70","author":"Anfuso","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000439083","article-title":"Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship","volume":"92","author":"Abdelaziz","year":"2015","journal-title":"Digestion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2014.08.024","article-title":"Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension","volume":"62","author":"Mookerjee","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0168-8278(18)30335-0","article-title":"Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH","volume":"68","author":"Lawitz","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients with Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"ref_29","first-page":"805A","article-title":"Patient-reported outcomes (PROs) in patients with primary sclerosing cholangitis (PSC) during treatment with cilofexor (GS-9674)","volume":"70","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref_30","first-page":"31A","article-title":"The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): A phase 2, randomized, placebo-controlled trial","volume":"70","author":"Kowdley","year":"2019","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2013.07.005","article-title":"Propranolol, a beta-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis","volume":"437","author":"McKee","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/1\/60\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:09:17Z","timestamp":1760159357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/1\/60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["biomedicines9010060"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9010060","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]}}}